cbdMD, Inc. has successfully completed the acquisition of assets from Twinlab Consolidated Holdings, Inc., a move that significantly expands its operations into the nutritional supplements market. This acquisition, finalized on October 30, 2026, allows cbdMD to diversify its product offerings beyond its current focus on CBD products.

The acquisition comes after cbdMD entered into an Asset Purchase Agreement on September 1, 2026, involving several parties including To Be Brands, LLC, a wholly owned subsidiary of cbdMD. The assets acquired include intellectual property, contracts, and inventory related to Twinlab's business of marketing and distributing nutritional supplements.

According to the filing, the assets will be acquired free of encumbrances, with cbdMD assuming certain debts and issuing shares as part of the transaction. The company will issue 2,229,805 shares of its common stock, valued at $1.00 each, to the secured creditor involved in the deal. This represents approximately 19.9% of cbdMD's outstanding shares as of the execution date of the agreement.

cbdMD aims to leverage this acquisition to strengthen its position in the perfumes, cosmetics, and other toilet preparations sector, as classified under SIC 2844. The company believes that adding established brands and products will help it capture a larger share of the growing nutritional supplement market.

The acquisition includes several subsidiaries of Twinlab, such as ISI Brands, Inc., Reserve Life Organics, LLC, and Resvitale, LLC. These brands are known for their diverse range of nutritional products, including vitamins, minerals, and sports nutrition items.

In connection with the acquisition, cbdMD has also entered into ancillary agreements to ensure a smooth transition and continued operation of the acquired businesses. This includes service agreements for certain employees of Twinlab who will remain with the company post-acquisition.

cbdMD's move to acquire Twinlab's assets is seen as a strategic effort to diversify its offerings and enhance its market presence. The company is expected to file additional financial statements related to the acquisition in the coming weeks, as required by SEC regulations.

The filing indicates that cbdMD will seek shareholder approval for additional shares to maintain the target percentage set forth in the acquisition agreement. This indicates a proactive approach to ensure compliance with NYSE regulations while expanding its capital base.

Overall, this acquisition marks a significant step for cbdMD as it looks to broaden its horizons in the health and wellness industry, potentially impacting competitors in the nutritional supplement market.